HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

BIBR 1532 increases arsenic trioxide-mediated apoptosis in acute promyelocytic leukemia cells: therapeutic potential for APL.

Abstract
The current treatment of acute promyelocytic leukemia with arsenic trioxide (ATO) has increased long-lasting complete remissions; however, a proportion of patients continues to die eventually as a result of disease recurrence. In an effort to enhance the effectiveness of the APL treatment, we designed experiments to evaluate the effects of ATO in combination with the lead compound of non-nucleoside inhibitor of telomerase, BIBR 1532. After combined treatments with BIBR 1532 and ATO, decreased cell viability index with a concomitant increase in apoptotic cell death was observed in NB4 leukemic cells. Apoptosis induced by the combined treatments was accompanied by elevated Bax/Bcl-2 molecular ratio and enhanced caspase 3 activation. Our study has also demonstrated that the combined treatment suppressed NB4 cell proliferative capacity and inhibited telomerase activity probably via transcriptional suppression of c-Myc and hTERT. In conclusion, this study may supply insight into the application of this new combination therapy to APL cells intrinsically less sensitive to routine therapies and suggested a novel combination therapy for patients with more aggressive disease; those who may not respond favorably to the arsenic mono-therapy.
AuthorsDavood Bashash, Seyed H Ghaffari, Farhad Zaker, Maryam Kazerani, Kebria Hezave, Saeed Hassani, Masomeh Rostami, Kamran Alimoghaddam, Ardeshir Ghavamzadeh
JournalAnti-cancer agents in medicinal chemistry (Anticancer Agents Med Chem) Vol. 13 Issue 7 Pg. 1115-25 (Sep 2013) ISSN: 1875-5992 [Electronic] Netherlands
PMID23293885 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Aminobenzoates
  • Antineoplastic Agents
  • Arsenicals
  • BIBR 1532
  • Naphthalenes
  • Oxides
  • Telomerase
  • Caspase 3
  • Arsenic Trioxide
Topics
  • Aminobenzoates (administration & dosage, pharmacology)
  • Antineoplastic Agents (administration & dosage, pharmacology)
  • Antineoplastic Combined Chemotherapy Protocols (administration & dosage, pharmacology)
  • Apoptosis (drug effects)
  • Arsenic Trioxide
  • Arsenicals (administration & dosage, pharmacology)
  • Caspase 3 (metabolism)
  • Cell Line, Tumor
  • Cell Proliferation (drug effects)
  • Cell Survival (drug effects)
  • Drug Synergism
  • Gene Expression Regulation, Neoplastic (drug effects)
  • Humans
  • Leukemia, Promyelocytic, Acute (drug therapy, genetics, metabolism)
  • Naphthalenes (administration & dosage, pharmacology)
  • Oxides (administration & dosage, pharmacology)
  • Telomerase (antagonists & inhibitors, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: